COVID 19, Paxlovid and the lesson from rare genetic diseases with naturally occurring protection from SARS-CoV-2 infection
Author:
Publisher
Springer Science and Business Media LLC
Subject
Nephrology
Link
https://link.springer.com/content/pdf/10.1007/s40620-022-01439-1.pdf
Reference9 articles.
1. Stefanelli LF, Gobbi L, Ravarotto V, Bertoldi G, Calò LA (2022) The counter-regulatory arm of the renin-angiotensin system and COVID-19: insights from Gitelman’s and Bartter’s syndromes. J Hypertens 40:648–649. https://doi.org/10.1097/HJH.0000000000003090
2. Resnick SJ, Iketani S, Hong SJ, Zask A, Liu H, Kim S, Melore S, Lin F-Y, Nair MS, Huang Y, Lee S, Tay NES, Rovis T, Yang HW, Xing L, Stockwell BR, Ho DD, Chavez A (2021) Inhibitors of coronavirus 3CL proteases protect cells from protease-mediated cytotoxicity. J Virol 95:e0237420. https://doi.org/10.1128/JVI.02374-20
3. Calò LA, Rigato M, Sgarabotto L, Ianesello L, Bertoldi G, Ravarotto V, Davis PA (2021) ACE2 and SARS-CoV-2 infection risk: insights from patients with two rare genetic tubulopathies. Gitelman’s and Bartter’s syndromes. Front Med 8:647319. https://doi.org/10.3389/fmed.2021.647319
4. Bertoldi G, Ravarotto V, Sgarabotto L, Davis PA, Gobbi L, Calò LA (2022) Impaired ACE2 glycosylation and protease activity lowers COVID-19 susceptibility in Gitelman’s and Bartter’s syndromes. J Intern Med 291:522–524. https://doi.org/10.1111/joim.13426
5. Calò LA, Davis PA, Rossi GP (2014) Understanding the mechanisms of angiotensin II signaling involved in hypertension and its long-term sequelae: insights from Bartter’s and Gitelman’s syndromes, human models of endogenous angiotensin II signaling antagonism. J Hypertens 32:2109–2119. https://doi.org/10.1097/HJH.0000000000000321
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Impaired ACE2 glycosylation and protease activity in Fabry disease protects from COVID‐19;Journal of Internal Medicine;2023-06-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3